Skip to main content
Fig. 2 | Trials

Fig. 2

From: Intranasal dexamethasone: a new clinical trial for the control of inflammation and neuroinflammation in COVID-19 patients

Fig. 2

Outline of the REVIVAL trial clinical protocol. Initially, patients will be informed about the clinical trial; if they accept and sign the consent, they will be randomized using the Sealed envelope® software. Group A will receive intranasal DXM; Group B will receive intravenous DXM. Both groups will be sampled on days 0, 3, 6, and 10 post-treatment to collect sera and nasopharyngeal swabs. Patients will be monitored throughout the study. The results will be tested for statistical differences between groups

Back to article page

Trials

ISSN: 1745-6215